Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques

[1]  A. Fleisher,et al.  Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease , 2017, Alzheimer's & dementia.

[2]  D. Brooks,et al.  Validation of an electronic image reader training programme for interpretation of [18F]flutemetamol β-amyloid PET brain images , 2016, Nuclear medicine communications.

[3]  W. Klunk,et al.  Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection , 2016, Acta neuropathologica communications.

[4]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[5]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[6]  Masanori Nakagawa,et al.  High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. , 2009, Archives of neurology.

[7]  Keith A. Johnson,et al.  P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees , 2006, Alzheimer's & Dementia.

[8]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[9]  A. Levey,et al.  Diffuse Plaques in the Striatum in Alzheimer Disease (AD): Relationship to the Striatal Mosaic and Selected Neuropeptide Markers , 1997, Journal of neuropathology and experimental neurology.

[10]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[11]  L. H. Hughes,et al.  Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer’s disease? , 1997, Acta Neuropathologica.

[12]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[13]  Stephen Sallowaya,et al.  Performance of [ 18 F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer’s disease , 2017 .

[14]  C. Buckley,et al.  Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology. , 2016, Journal of Alzheimer's disease : JAD.

[15]  S. Hirai,et al.  Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated byβ protein immunostain , 2004, Acta Neuropathologica.